David Mangold, PA
Medical · Kalispell, MTNPI 1164533618
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (43.0%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. 18 manufacturers reported payments, led by Blueprint Medicines Corporation at 34.6% of the total. Reporting peaked in 2021 at $1,522 and has fallen 96.4% since, to $55 in 2025. Among medical clinicians in MT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 51 payments — averaging $66.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Blueprint Medicines Corporation$1K
- Novartis$1K
- AstraZeneca$248
- Merck$157
- Regeneron Healthcare Solutions, Inc.$139
- Aimmune Therapeutics, Inc.$125
- plus $504 from 12 others
What the payments were for
- Consulting fees$1,02830%
- Speaking & faculty fees$88126%
- Food & beverage$1,45543%
- Education$221%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Blueprint Medicines Corporation | 9 | $1,172 |
| Novartis | 2 | $1,041 |
| AstraZeneca | 9 | $248 |
| Merck | 1 | $157 |
| Regeneron Healthcare Solutions, Inc. | 5 | $139 |
| Aimmune Therapeutics, Inc. | 1 | $125 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $100 |
| Optinose US, Inc. | 1 | $69 |
| Sanofi | 3 | $66 |
| Astellas Pharma US Inc | 2 | $49 |
| Amgen(2 entities) | 3 | $45 |
| Genentech USA, Inc. | 4 | $41 |
| ARS Pharmaceuticals Operations, Inc. | 2 | $40 |
| GSK | 2 | $29 |
| Pfizer | 2 | $25 |
| Incyte Corporation | 1 | $16 |
| LEO Pharma Inc. | 1 | $13 |
| Teva Pharmaceuticals USA, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,386 in reported general payments places this provider in the 90th percentile of 134 medical providers in Montana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NucalaMepolizumab | 14 | $49,068 |
| XolairOmalizumab | 16 | $44,319 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 21 | $18,574 |
| Breo ElliptaFluticasone/Vilanterol | 18 | $8,627 |
| Advair HfaFluticasone Propion/Salmeterol | 14 | $4,740 |
| Arnuity ElliptaFluticasone Furoate | 21 | $4,449 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 15 | $2,422 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 16 | $517 |
| Azelastine Hcl | 24 | $370 |
| Famotidine | 18 | $333 |
| Fluticasone Propionate | 13 | $100 |
| Gabapentin | 13 | $52 |
| Prednisone | 12 | $41 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKNucala, Trelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $29 | $80,71974 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 134 medical providers in Montana.
Other medical in Kalispell
- Mackenzie GeorgeKalispell$9K
- Maureen KunzKalispell$2K
- Libbie LappKalispell$2K
- Brooke SchmidtKalispell$1K
- Matthew ZemackeKalispell$606
- David BrostGreat Falls$7K
- Erin LafavorBillings$6K
- Heidi DrescherMissoula$6K
- Gabriel BlomquistBillings$5K
- Michael HinesBillings$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.